Eli Lilly and Company: Neoplasm Metastasis trials

The registry lists 72 Neoplasm Metastasis studies with Eli Lilly and Company as lead sponsor. 8 are open to participants now and 42 have results posted.

Phase 1 46Phase 2 16Phase 3 10Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid TumorsAvailableNCT07675057
• A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary TractRecruitingNCT07218380Phase 3
• A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerRecruitingNCT07213804Phase 3
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingNCT07174336Phase 3
• A Study of LY4257496 in Participants With Cancer (OMNIRAY)RecruitingNCT07114601Phase 1
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsRecruitingNCT06465069Phase 1
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingNCT06119581Phase 3
• FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3RecruitingNCT05614739Phase 1
• CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's SarcomaActive, not recruitingNCT05440786Phase 2Results posted
• A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)Active, not recruitingNCT05288166Phase 3Results posted
• Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast CancerActive, not recruitingNCT05169567Phase 3Results posted
• A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerActive, not recruitingNCT04975308Phase 3Results posted
• A Study of Abemaciclib in Indian Women With Advanced Breast CancerCompletedNCT04707196Phase 4Results posted
• A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced CancerCompletedNCT04148937Phase 1Results posted
• A Study of AK-01 (LY3295668) in Solid TumorsCompletedNCT03092934Phase 1/2Results posted
• A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic CancersCompletedNCT02919696Phase 1Results posted
• A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract CancerActive, not recruitingNCT02711553Phase 2Results posted
• A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the BodyCompletedNCT02688088Phase 1Results posted
• A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With CancerCompletedNCT02677116Phase 1Results posted
• A Study of LY3076226 in Participants With Advanced or Metastatic CancerCompletedNCT02529553Phase 1Results posted
• A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02411591Phase 1Results posted
• A Study of LY3022855 In Participants With Breast or Prostate CancerCompletedNCT02265536Phase 1Results posted
• A Study of LY3164530 in Participants With CancerCompletedNCT02221882Phase 1Results posted
• A Study of LY2835219 in Participants With CancerCompletedNCT02117648Phase 1Results posted
• A Study of LY2835219 in Japanese Participants With Advanced CancerCompletedNCT02014129Phase 1Results posted
• A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their BodyTerminatedNCT02014116Phase 1Results posted
• A Study of LY2940680 in Japanese Participants With Advanced CancersCompletedNCT01919398Phase 1Results posted
• A Study of LY3039478 in Participants With Advanced CancerCompletedNCT01695005Phase 1Results posted
• A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has SpreadCompletedNCT01648764Phase 1Results posted
• A Dose-Escalation Study in Participants With Advanced CancerCompletedNCT01524224Phase 1Results posted
• A Study of LY3007113 in Participants With Advanced CancerCompletedNCT01463631Phase 1Results posted
• A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung CarcinomaCompletedNCT01439568Phase 2Results posted
• A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell CarcinomaTerminatedNCT01391130Phase 2Results posted
• A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic CancerCompletedNCT01373164Phase 1/2Results posted
• A Safety Study in Participants With Advanced Solid TumorsTerminatedNCT01284335Phase 1Results posted
• A Study of LY2584702 in Solid TumorsCompletedNCT01241461Phase 1Results posted
• A Study in Advanced CancerCompletedNCT01226485Phase 1Results posted
• A Study for Participants With Advanced CancerCompletedNCT01214629Phase 1Results posted
• A Phase 1 Study of LY2874455 in Participants With Advanced CancerCompletedNCT01212107Phase 1Results posted
• A Tasisulam and Midazolam Drug Interaction Study in Cancer PatientsTerminatedNCT01209832Phase 1Results posted
• Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid TumorsCompletedNCT01199822Phase 1Results posted
• Notch Inhibitor in Advanced CancerCompletedNCT01158404Phase 1Results posted
• A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid TumorsTerminatedNCT01115803Phase 1Results posted
• Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval ChangesCompletedNCT01017731Phase 2Results posted
• A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic MelanomaTerminatedNCT01006252Phase 3Results posted
• A Study of LY573636-sodium in Patients With Metastatic Breast CancerCompletedNCT00992225Phase 2Results posted
• Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and AdenocarcinomaCompletedNCT00917384Phase 3Results posted
• A Study for Participants With Pancreatic CancerCompletedNCT00839332Phase 1/2Results posted
• A Study of Cixutumumab (IMC-A12) in Islet Cell CancerCompletedNCT00781911Phase 2Results posted
• Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to ChemotherapyCompletedNCT00083720Phase 2Results posted
• A Study of LY4175408 in Participants With Advanced CancerActive, not recruitingNCT07046923Phase 1
• A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsActive, not recruitingNCT06607185Phase 1
• A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsActive, not recruitingNCT06561685Phase 1
• A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsActive, not recruitingNCT06238479Phase 1
• A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic CancerCompletedNCT03027284Phase 1
• A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic CancerCompletedNCT02860780Phase 1
• A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung CancerWithdrawnNCT02831491Phase 2
• A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic MalignanciesCompletedNCT02572687Phase 1
• A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced CancersCompletedNCT02514603Phase 1
• A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced CancerCompletedNCT02124148Phase 1
• Study of LY2157299 in Japanese Participants With CancerCompletedNCT01722825Phase 1
• A Study of LY3023414 in Participants With Advanced CancerCompletedNCT01655225Phase 1
• A Study of LY2624587 in Patients With Advanced CancerCompletedNCT01139788Phase 1
• A Study in Patients With Advanced or Metastatic CancerCompletedNCT01115751Phase 1
• Chemotherapy in Treating Patients With Lung CancerCompletedNCT01067794
• An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung CarcinomaCompletedNCT00207116Phase 1
• Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast CancerCompletedNCT00072865Phase 2
• Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal CarcinomaCompletedNCT00044863Phase 2
• A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the UrotheliumCompletedNCT00035061Phase 2
• A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.CompletedNCT00035035Phase 3
• A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the UrotheliumCompletedNCT00034593Phase 2
• ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic CancerCompletedNCT00034463Phase 1